JNJ
Johnson & Johnson, a global healthcare leader, has kicked off the year on a high note, delivering impressive growth in its first quarter of 2026. The company's operational sales growth clocked in at 6.4%, beating consensus estimates and setting the stage for an exciting year ahead. In
JNJ
Johnson & Johnson has delivered a strong second quarter performance, with operational sales growth of 4.6% across its business. The company reported $15 billion in quarterly sales from its Innovative Medicines segment, driven by double-digit growth across three brands: DARZALEX, CARVYKTI, and other products. This achievement is particularly impressive
JNJ
Johnson & Johnson, a multinational healthcare company, recently reported its first-quarter results for 2025, showcasing impressive performance across its commercial, R&D, and supply chain capabilities. The company's Chairman and CEO, Joaquin Duato, described the period as a testament to their strength in execution and a reflection